
Defiance ETFs has launched the Defiance Autism Impact ETF (NASDAQ:ASD), a first-of-its-kind ETF designed to provide investors with exposure to companies developing products, therapies, services and technologies that support individuals with autism and related neurodevelopmental conditions.
• Defiance Autism Impact ETF shares are showing limited movement. Where is ASD stock headed?
The launch marks the culmination of a strategy first outlined in a March regulatory filing and introduces a rare combination of thematic investing and philanthropy. The fund arrives as investors continue to show interest in health care innovation themes ranging from AI-powered drug discovery to next-generation therapeutics and medical technologies.
Defiance CEO Matthew Bielski said the fund was inspired by his personal experience raising a profoundly autistic child. They noted autism is a broad spectrum encompassing neurological, developmental, behavioral and biological challenges that affect individuals differently, and expressed hope that the ETF will help channel capital toward companies working to improve quality of life for affected individuals and their families.
Key Features of ASD ETF
ASD stands apart from traditional health care ETFs by combining exposure to autism-related innovation with a long-term charitable mission, offering investors a way to participate in advancing therapies, diagnostics and support services while contributing to autism-focused causes.
Photo: Shutterstock